Header - Therapeutics

Therapeutics

Antigen-specific B-Cell Enrichment (Reactivation)

What is Reactivation?

Reactivation is NeoClone's patented process to reactivate antigen-specific lymphocytes for antibody development. We have established specific culture conditions which enrich for class-switched, high affinity B cells over non-target cells. Our platform captures desired affinity characteristics and the diversity of the B cell response.

Basic Enrichment Process

  • Selection of activated lymphocytes
  • Culture in supportive media
  • Expansion of antigen-specific Ig -secreting cells
  • Reduction of non-specific Ig-secreting cells
  • Long-term culture

Sample ELISPOT examining total murine splenocytes (top row) and the enriched B-cell population (bottom row). Wells were coated with specific antigen (left 2 columns), an irrelevant antigen (middle 2 columns) or total IgG (right 2 columns) and the cell populations were incubated in the wells in duplicate.

Antigen-Specific Human B-Cell Enrichment

It turns out that murine B cell reactivation technology is a natural fit for transgenic mouse companies seeking high quality, fully human antibodies. In 2012, the National Institutes of Health awarded NeoClone Biotechnology a grant for the project: “Reactivation of human cells for novel fully human Ab platform”. The Principal Investigator was Rachel Kravitz, PhD, NeoClone’s Director of Research.

Neoclone’s hu-mAb platform (which has been marketed under the NeoAb® process) offers several advantages over existing technologies;

  • The mAbs are fully human, having been developed from human immune cells in a SCID mouse model.
  • The approach does not require immunizing patients or access to convalescent blood, therefore the platform is amenable for mAb development using de novo immunization against any therapeutic target.
  • mAbs developed using this approach will likely have higher affinities than Abs generated by library-based methods since reactivation focuses on selection of affinity-matured cell targets that proliferate in very low Ag levels.
  • hu-mAbs generated using the NeoAb® process can have fully-human glycosylation patterns, a distinct advantage over human mAbs expressed in non-human cells.

In addition, this process enables NeoClone to select for or against certain secondary characteristics such as Ab-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Thus, Neoclone’s approach to hu-mAb production can circumvent the limitations of current technologies, and promote development of new therapeutic treatments by lowering the costs of fully-human mAbs.

NeoClone's hu-mAb platform increases the number of class switched, affinity matured, antigen specific B cells, while eliminating all other cell types in the process. This can potentially be a strong candidate process to work in transgenic mouse models as well. NeoClone is currently exploring collaborations with transgenic mouse companies looking for a robust method to increase the number of cells producing fully-human antigen specific antibodies.

Market Requirements for Therapeutic antibodies

  • Fully human (Fewer safety issues / better efficacy)
  • Diversity (Need to deliver multiple good candidates for client evaluation)
  • Affinity (Need to deliver candidates with a range of affinities to allow for the selection of the most appropriate antibodies)
  • Specific (de novo immunizations)
  • Reproducibility - Quality (Need to generate an appropriate number of candidates each time)
  • Reasonable Timeframe (Quickly to market)

NeoClone's platform technology has the potential to generate fully human, high affinity hu-mAbs at an affordable price. This proprietary approach provides an economical solution for developing high affinity hu-mAbs for biotech & pharmaceutical companies as well as academic researchers interested in reagents for pre-clinical trials.

If you are interested discussing how we can help you in developing the very best therapeutic or pre-clinical antibodies, contact us today at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .